Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Cancer cell

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424130100 - IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL

424172100 - Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell (e.g., honey, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177099GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE - Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.07-21-2011
20090123483ANTI-CCR7 RECEPTOR ANTIBODIES FOR THE TREATMENT OF CANCER - Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumour cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumour is disclosed, thus providing an alternative therapy for treatment of cancer which tumour cells express a CCR7 receptor.05-14-2009
20090123484Methods for Diagnosing and Treating Kidney Cancer - Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.05-14-2009
20100062002Brain Endothelial Cell Expression Patterns - To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECS derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.03-11-2010
20090191221ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.07-30-2009
20100074908Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.03-25-2010
20120244170TREATING CANCER BY MODULATING MEX-3 - The present invention relates to a method for treating cancer in a subject by modulating MEX-3, by administering to said subject a therapeutically effective amount of a modulator of MEX-3.09-27-2012
20100074909Combinations for the treatment of cancer - This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.03-25-2010
20120207771FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR FOLATE RECEPTOR ALPHA-EXPRESSING CANCERS - The present invention provides methods and kits for assessing whether a subject is afflicted with an FRα-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FRα-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FRα-expressing cancer, and methods of stratifying a subject with an FRα-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FRα) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FRα in a control sample.08-16-2012
20130039930BIOMARKER FOR SENSITIVITY TO THERAPY WITH A NOTCH INHIBITOR - Described herein are materials and methods for identifying subjects that would benefit from Notch-targeted therapy.02-14-2013
20100104586Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors - A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.04-29-2010
20130045220Microvesicle Membrane Protein And Application Thereof - Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binding agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment.02-21-2013
20100092491ANTI-EPCAM ANTIBODY AND USES THEREOF - An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumour selectivity.04-15-2010
20120164161Antibodies and Uses Thereof - The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.06-28-2012
20110200621COMPOSITIONS AND METHODS FOR TREATING CANCER - This invention generally relates to compositions and methods for targeted delivery of chemotherapeutic agents to cancerous and pre-cancerous cells, thereby treating a cancer in a subject.08-18-2011
20090304716TREATMENT OF METASTATIC BREAST CANCER - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.12-10-2009
20130058960COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.03-07-2013
20110038880PARASPORIN-1 RECEPTOR AND USE THEREOF - The receptor of parasporin-1 has been found to be beclin-1. Based on the finding, the present invention provides a method of determining the sensitivity of a cell to parasporin-1, comprising measuring the expression level of beclin-1 polypeptide on the cell membrane or in a membrane fraction of a cell; an inhibitor of the cytotoxicity of parasporin-1, containing beclin-1 polypeptide etc.; a method of screening for a substance capable of inhibiting the cytotoxicity of parasporin-1, comprising evaluating the degree of binding of parasporin-1 to beclin-1 polypeptide in the presence of a test substance; a cell death inducer containing an antibody that specifically recognizes beclin-1 polypeptide; a method of screening for a substance capable of inducing cell death, comprising evaluating the binding of a test substance to beclin-1 polypeptide, and the like.02-17-2011
20110059114Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells - Compositions and uses of gamma secretase inhibitors (GSIs) for the treatment and inhibition of gliomas in subjects in need thereof are provided. Methods for administering gamma secretase inhibitors in association with radiation for the treatment of radiation resistant gliomas are described. Compositions for the inhibition of Notch signaling and activity are provided.03-10-2011
20120308582MOLECULES AND METHODS FOR MODULATING TMEM16A ACTIVITIES - The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.12-06-2012
20130064838ENHANCED DEATH RECEPTOR AGONISTS - Methods and compositions for treatment of cancer in a human patient comprising administering a therapeutically effective amount of an Fc-polypeptide agonist of DR5 having high-affinity to FCGR3A. Methods of making the Fc-polypeptides are provided.03-14-2013
20080267979Anti-Glypican-3 Antibody - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.10-30-2008
20090047295Methods and Compositions for Reducing Stemness in Oncogenesis - The invention provides methods and compositions for reducing the number of cancer stem cells in a mixed population of differentiated cells (for example, cancer cells) and cancer stem cells. The cancer stem cells, if present, can be more resistant to traditional drug-based therapies and can provide a source for new, differentiated cancer cells associated with the development of drug-resistance and more aggressive phenotypes. When combined with traditional cancer therapies, for example, drug-based therapies, the methods and compositions of the invention provide a more effective way for treating cancer and can provide a model system for developing new cancer therapies and new treatment modalities.02-19-2009
20090010944OLIGOSIALIC ACID DERIVATIVES, METHODS OF MANUFACTURE, AND IMMUNOLOGICAL USES - The invention relates to methods of producing, and compositions comprising, an isolated alpha (2→8) or (2→9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2→8) or (2→9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2→8) or (2→9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2→8) or (2→9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of 01-08-2009
20090136523ANTI-CD26 ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.05-28-2009
20130164309ANTIBODIES TO THE B12-TRANSCOBALAMIN RECEPTOR - The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.06-27-2013
20080267977Combined immunological agent and sensitizing agent for the treatment of cancer - A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of an apoptosis-inducing immunologic agent, and a sensitizing agent. When used in cancer therapy, the two agents in combination enhance the anti-cancer treatment efficacy obtained with the immunologic agent or the sensitizing agent alone, by a supraadditive amount.10-30-2008
20110280888ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.11-17-2011
20100255010ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.10-07-2010
20090202570PM-2 ANTIBODIES, FUNCTIONAL FRAGMENTS AND METHODS FOR TREATING METASTASIS - The invention provides PM-2 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a PM-2 antibody or functional fragment thereof effective to treat metastasis of the neoplasia, tumor or cancer in the subject.08-13-2009
20120231021ANTIBODIES SPECIFICALLY BINDING TO THE EPIDERMAL GROWTH FACTOR RECEPTOR - Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.09-13-2012
20130216559Stromal Antigen 2 (STAG2) Compositions and Methods - Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.08-22-2013
20090053244Modified vaccinia virus strains for use in diagnostic and therapeutic methods - Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.02-26-2009
20120087931THERAPEUTIC AND DIAGNOSTIC ANTI-HSP70 ANTIBODIES - Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.04-12-2012
20090130125COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER - The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations.05-21-2009
20100136031ANTI-CXCR1 COMPOSITIONS AND METHODS - The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).06-03-2010
20100189725P53 MODULATOR AND CANCER TARGET - Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukaemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.07-29-2010
20100034834MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS - The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD402-11-2010
20110262463SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS - The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.10-27-2011
20110262464Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3 - The present invention is based, in part, on the discovery that GOLPH3 plays a role in cancer, including lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring cancer, e.g., lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma.10-27-2011
20080311131Human Mob-5 (IL-24) receptors and uses thereof - The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of detecting cancer by detecting the presence of the Mob-5 receptor.12-18-2008
20120141506TREATMENT OF NON-PROLIFERATIVE CYSTIC DISEASE - The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.06-07-2012
20120321646Methods for Enhancing Anti-Tumor Antibody Therapy - Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.12-20-2012
20120107330ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1 - The present invention relates to anti-Tumor Necrosis Factor 1 (TNFR1, p55, CD120a, P60, TNF receptor superfamily member 1A, TNFRSF1A) antagonists for partially inhibiting TNFR1 useful for the treatment and/or prevention of TNFR1-mediated diseases or conditions such as arthritis, psoriasis, Crohn's disease, COPD, lung inflammatory conditions and asthma. The invention further relates to methods, uses, formulations, compositions and devices comprising or using such anti-TNFR1 antagonists.05-03-2012
20090202569Prophylactic/Therapeutic Agent for Cancer - The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that inhibits expression of a gene for an enzyme belonging to the acyl-CoA synthase family, with at least one selected from a substance that inhibits the activity of fatty acid synthase and a substance that inhibits expression of a fatty acid synthase gene and the like can be used as a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells.08-13-2009
20110200620B7-H1 AND METHODS OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER - The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.08-18-2011
20110200619PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF - Disclosed are compounds effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.08-18-2011
20090285836USE OF SALINOSPORAMIDE A TO INHIBIT METASTASIS - The present invention relates to methods and compositions for treating and evaluating metastatic conditions.11-19-2009
20100062001Antibodies for selective apoptosis of cells - A recombinant isolated antibody and a pharmaceutical composition containing same, capable of specifically recognizing an MHC-peptide complex with an affinity in a nanomolar range and of inducing apoptosis in cancer or pathogen infected cells is provided. Also provided are method for treating and diagnosing cancer or pathogen infection in a subject using the recombinant isolated antibody of the present invention.03-11-2010
20120294874Method for Producing T Cell Receptor-Like Monoclonal Antibodies and Uses Thereof - Methods are provided for producing T cell receptor (TCR) like antibodies that recognize peptides displayed in the context of HLA molecules. Antibodies produced by methods provided herein have the specificity of a TCR and can be used as therapeutic, diagnostic and research reagents. Also provided are TCR-like antibodies which recognize Epstein-Barr virus (EBV) peptides displayed in the context of HLA molecules and are useful for the detection and treatment of EBV and EBV-linked diseases.11-22-2012
20100221267PDGFR BETA-SPECIFIC INHIBITORS - The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.09-02-2010
20110206702COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.08-25-2011
20100291113Treatment of Proliferative Disorders Using Antibodies to PSMA - Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA. In some embodiments, the method comprises restricting folate intake by the patient. Methods of monitoring cancer therapy are provided as well as kits for treating cancer and kits for monitoring cancer therapy.11-18-2010
20100291111Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation - The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.11-18-2010
20110268749TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2 - Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13Rα11-03-2011
20110008371METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS - Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.01-13-2011
20120294872Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung - A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.11-22-2012
20100209439Anti-Prominin-1 Antibody having ADCC Activity or CDC Activity - An objective of the present invention is to provide antibodies that bind to Prominin-1 and have ADCC activity and/or CDC activity, and pharmaceutical compositions containing those antibodies as an active ingredient.08-19-2010
20090053243Anti-IgSF4 Antibody and Utilization of the Same - It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.02-26-2009
20110206703GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.08-25-2011
20090028879NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.01-29-2009
20090028878NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.01-29-2009
20090028877Antibody Composition Specifically Binding to Ganglioside Gm - An anti-ganglioside GM2 antibody composition having enhanced effector function which is useful as a medicament has been desired. The present invention provides an antibody composition comprising an antibody molecule which specifically binds to ganglioside GM2 and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.01-29-2009
20090162382OPTIMIZED CA9 ANTIBODIES AND METHODS OF USING THE SAME - The present invention describes antibodies that target CA9, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.06-25-2009
20090136524COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.05-28-2009
20130122020ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES - The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.05-16-2013
20130122021B7-H3 IN CANCER - Methods of determining the prognosis of a subject with cancer and determining risk of cancer progression by assessing expression of B7-H3. Methods of reducing B7-H3 levels and/or activity.05-16-2013
20110223181Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium - Provided herein are methods for treating ovarian serous papillary carcinoma by delivering 09-15-2011
20090022741NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.01-22-2009
20090081241Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.03-26-2009
20110223180METHODS AND COMPOSITIONS RELATED TO A MULTI-METHYLATION ASSAY TO PREDICT PATIENT OUTCOME - Methods and compositions for the prognosis and classification of cancer, especially brain tumor, are provided. For example, in certain aspects methods for cancer prognosis using methylation analysis of selected biomarkers are described.09-15-2011
20100003265Isolation, expansion and uses of tumor stem cells - Disclosed are methods for isolating cell populations enriched in tumor stem cells (cancer stem cells), and isolated cell populations substantially enriched in cancer stem cells that are tumorigenic in vivo. Also provided are new methods of tumor diagnosis and classification and personalized methods of treatment for subjects with tumors, based on the availability of populations of cancer stem cells derived from the subject's tumor using the disclosed methods.01-07-2010
20100178298Destruction of Tumor Cells by Trifunctional Bispecific Antibodies With Low to Medium Expression Levels of Tumor-Associated Target Antigens - The present invention describes the use of trifunctional bispecific antibodies for the preparation of a pharmaceutical composition for the prophylaxis and treatment of tumor diseases. It has been found that said trifunctional bispecific antibodies are binding to tumor-associated antigens selected from Her2/neu, CD20, EpCAM, G250, proteoglycans, GD3, GD2, MHC II, EGF-R and CEA, wherein said tumor-associated antigens are expressed on said tumor cell with a low to medium expression level only.07-15-2010
20100166779Monoclonal Antibodies Against Claudin-18 for Treatment of Cancer - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.07-01-2010
20090053245Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood - A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood disease or steroid therapeutic or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the anticancer therapeutic as well as enhanced efficacy not due to compound degradation. It is preferred that the pharmacokinetic modulating moiety has a mass of less than 1100 Daltons.02-26-2009
20100183630Tat-005 and Methods of Assessing and Treating Cancer - Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.07-22-2010
20110110958COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA - The invention provides compositions and methods for the treatment of neoplasias that are cytotoxic to neoplastic cells or that modulate JAZ expression, subcellular localization, or biological activity.05-12-2011
20120195916METHOD OF TREATING CANCER BY INHIBITING TRIM59 EXPRESSION OR ACTIVITY - A method of treating cancer in a mammal is provided comprising the step of inhibiting TRIM59 expression or activity in the mammal. TRIM59 expression may also be utilized in methods of diagnosing cancer in a mammal.08-02-2012
20100239598POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF - Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.09-23-2010
20130216558COMPOSITIONS AND METHODS FOR TREATING HAEMATOLOGICAL PROLIFERATIVE DISORDERS OF MYELOID ORIGIN - The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.08-22-2013
20100158926ANTIBODIES TO ERBB2 - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically hind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.06-24-2010
20100322950COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS - Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD.12-23-2010
20100322949METHODS FOR DIAGNOSING AND TREATING ASTROCYTOMAS - The invention relates to the identification of astrocytoma markers, astrocytoma stem cells and markers of such stem cells, and diagnostic, prognostic and therapeutic methods based on an understanding of the markers and cells.12-23-2010
20100221266METHODS TO REGULATE MIRNA PROCESSING BY TARGETING LIN-28 - The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject.09-02-2010
20090110688COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer.04-30-2009
20080267978Anti-angiogenic targets for cancer therapy - The use of inhibitory anti-α2β1 integrin antibodies to inhibit tumor neoangiogenesis, slow tumor growth, treat abnormal angiogenesis, treat integrin-mediated disorders and inhibit endothelial cell proliferation.10-30-2008
20100297152METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER - Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.11-25-2010
20130136755MLK4 GENE, A NEW DIAGNOSTIC AND PROGNOSTIC MARKER IN CANCERS - An in vitro diagnostic method for determining invasive potential of cancer comprising measuring MLK4 gene expression in a cancer cell sample, wherein MLK4 gene overexpression is indicative of an invasive cancer, preferably a colorectal, bladder, breast, gastric, melanoma, lung, ovary or GMB cancer.05-30-2013
20130142812ANTIBODY AND USE THEREOF - A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.06-06-2013
20110027296ANTIBODIES FOR TREATING CANCER - The invention relates to the use of an antibody or a fragment thereof, specific against substance P, for the manufacture of a medicament for therapeutic treatment of a cancer expressing NK1 receptor and/or a ErbB receptor family member (i.e. the epidermal growth factor receptors family), by direct administration to a mammal, including a human. The administration of an antibody against substance P to a panel of breast cancer cell lines, inhibits HER2 activation and expression, causing a downregulation of different genes involved in cell cycle progression, like cyclin D1, cyclin E, cdk4 and cdk2. A decrease in proliferation and an arrest in G02-03-2011
20110008372ENHANCEMENT OF LIGHT ACTIVATED DRUG THERAPY THROUGH COMBINATION WITH OTHER THERAPEUTIC AGENTS - The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations.01-13-2011
20110008370NOVEL USE OF FLJ25416 GENE - Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.01-13-2011
20110110959ANTI-P2X7 PEPTIDES AND EPITOPES - The invention relates to the identification of a novel epitope on non-functional P2X05-12-2011
20110027297Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing - The invention relates to methods involving MS4A12 and agents targeting MS4A12 which are useful for therapy, diagnosis and testing of disease states, in particular cancer diseases. In particular, the invention relates to agents which reduce or inhibit expression or activity of MS4A12, compositions containing these agents, and methods for reducing, determining, or increasing the responsiveness of a cell towards EGF.02-03-2011
20100124555Compositions and Methods for Treating Pancreatic Tumors - The present invention relates to a method for producing an antigen-binding compound suitable for use in the treatment of cancer, the antigen-binding compounds and their uses.05-20-2010
20110243965ANTIBODIES AGAINST DOMAINS OF LAMININ-332 - Antibodies against various domains of laminin-332 are discussed herein. The antibodies reduce the adhesion and matrix binding properties of laminin-332, inhibiting tumor growth and metastasis in vivo. Pharmaceutical compositions and methods of using the antibodies for diagnostic, prophylactic, and/or therapeutic purposes are disclosed.10-06-2011
20110064748PHARMACEUTICAL COMBINATION AND METHOD FOR TREATING TUMOR - Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I):03-17-2011
20100021479Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues - The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.01-28-2010
20100183631Antibodies Directed to HER-3 and Uses Thereof - The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.07-22-2010
20110081362TREATMENT OF CANCER - Described herein are methods based, in part, on the discovery of genes or gene products that can be down-modulated to inhibit the growth and survival of a cell, such as a cancer cell. In one embodiment, the genes or gene targets are preferentially expressed in a cell having an activating Ras mutation (e.g., a cancer cell), which permits selective inhibition of growth in cells bearing an activating Ras mutation without affecting cells lacking enhanced Ras activity. In addition, the methods described herein provide for determining cancer prognosis in an individual bearing an activating Ras mutation.04-07-2011
20120201837USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein.08-09-2012
20120201838METHOD FOR SCREENING ANTICANCER AGENT OR SIP1/ZEB2 INHIBITOR USING INTEGRIN ALPHA 5 - The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.08-09-2012
20110212113Monoclonal Antibody SC104 and Derivative Thereof Specifically Binding to a Sialyltetraosyl Carbohydrate as a Potential Anti-Tumor Therapeutic Agent - The present invention provides an isolated specific binding member capable of binding a sialyltetraosyl carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.09-01-2011
20120034244METHODS OF TREATING SECONDARY BONE TUMORS WITH ANTIBODIES AGAINST PDGFR ALPHA - The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.02-09-2012
20110250213ANTIBODIES TO CD122 - The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.10-13-2011
20090022740NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.01-22-2009
20090324616DIFFERENTIAL CYTOKINE EXPRESSION IN HUMAN CANCER - The invention concerns a method for diagnosing a cancer type, whereby the expression of anti-apoptotic cytokines is determined in the tumour cells. The differential diagnosis of the present invention is used to classify tumour disorders and to recommend the required treatment and to monitor the progress and response to the treatment.12-31-2009
20090317407AUGMENTATION OF IMMUNE RESPONSE TO CANCER VACCINE - Methods are disclosed for stimulating an immune response against a target antigen, such as one or more tumor associated antigens. In particular examples the method includes reducing the number of CD4+ T cells in a subject after the subject receives a first dose of an immunogenic composition that includes the target antigen (such as a cancer vaccine), wherein the subject has a tumor that expresses the target antigen. The subject is administered a second dose of the immunogenic composition, thereby stimulating an immune response against the target antigen. In some examples the method also includes administering to the subject peripheral blood mononuclear cells (PBMCs) (for example a population of PBMCs depleted of CD25 cells, CD81 cells, CD13412-24-2009
20090311272METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.12-17-2009
20120231020MARKERS FOR SELECTING PERSONALIZED THERAPIES FOR THE TREATMENT OF CANCER - The invention relates to the identification of aprataxin (APTX) expression levels as a marker for the response to topoisomerase I inhibitor-based therapies in patients with cancer and, more particularly, colon cancer. The invention also relates to methods for treating patients with cancer who have low APTX expression levels by means of administering a topoisomerase I inhibitor to said patients.09-13-2012
20110165178DIAGNOSIS OF PROSTATE CANCER - The present invention relates to vitro diagnosis methods of prostate cancer from a test biological sample, comprising measuring the expression level of KIAA0153 in said test biological sample, as well as to methods for screening compounds inhibiting KIAA0153 gene expression or biological activity and uses of such KIAA0153 inhibiting compounds.07-07-2011
20110165179THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer.07-07-2011
20110020370SLC7A5 DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of SLC7A5 in the test cell sample or fluid sample as compared to the level of expression of SLC7A5 in a control cell sample or fluid sample isolated from a normal subject.01-27-2011
20110027295Adenosine Receptor Agonists and Antagonists to Modulate T Cell Responses - Described are uses of A2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing T-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents. The application provides methods of treatment and prevention based on the long term effects of the compounds on T cell responses.02-03-2011
20100285038Factor Involved in Metastasis and Uses Thereof - The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell motility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.11-11-2010
20100330105Anticancer Combination Therapies - Methods for treating or preventing hyperproliferating diseases, e.g., cancer, are described. A method may comprise administering to a subject in need thereof a therapeutically effective amount of a chemotherapeutic agent and a DNA vaccine.12-30-2010
20100330106Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided.12-30-2010
20110097343DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES - The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).04-28-2011
20090175884MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS - Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein, PrP, which has been identified on various cancer cell lineages.07-09-2009
20110189205METHODS OF TREATING CANCER USING AN AGENT THAT MODULATES ACTIVITY OF THE CALCITONIN-GENE RELATED PEPTIDE ("CGRP") RECEPTOR - The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.08-04-2011
20110189203IMMUNOGLOBULIN CONSTRUCTS - The present invention relates to protein and polypeptide constructs that comprise single variable domains that are linked to an Fc portion. The immunoglobulin constructs comprise two polypeptide chains in which each polypeptide chain comprises two or more single variable domains that are linked, usually via a suitable hinge region or linker, to one or more constant domains that, together, form an Fc portion. The invention also relates to polypeptide chains that form part of such constructs and/or that can be used to form such constructs. The invention further relates to nucleotide sequences and nucleic acids that encode or can be used to express such constructs or polypeptide chains; to methods for producing such constructs and polypeptides chains; to compositions (and in particular pharmaceutical compositions) that comprise such constructs or polypeptide chains; and to uses of such constructs, polypeptide chains or compositions.08-04-2011
20110189204Treatment of Disease with Proteasone Inhibitors - A method is provided for treating cancer in a patient comprising administering to said patient a proteasome inhibitor at least three days a week.08-04-2011
20100028365METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Methods and compositions are provided for the diagnosis and treatment of gastric cancers associated with amplification or overexpression of the c-Myb gene.02-04-2010
20120148607ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.06-14-2012
20110091485MODULATION OF CELL JUNCTIONS - The present invention provides methods of modulating cell junctions via the Gp140 membrane protein. Gp140 agonists and antagonists are provided, including activating and non-activating antibodies of Gp140, as well as compositions including the same. Methods of treatment including administration of a Gp140 agonist or antagonist are also provided. Finally, implants having a Gp140 modulator coupled thereto are provided.04-21-2011
20100255011COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF COMPLEMENT REGULATORY PROTEINS ON TARGET CELLS - This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.10-07-2010
20090285837HER2 ANTIBODY COMPOSITION - A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.11-19-2009
20110070246Antibodies Against CDCP1 for the Treatment of Cancer - The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.03-24-2011
20110070245IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER - IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P<0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs encoding a variety of proteins involved in signal transduction, cell-cycle progression, cell adhesion and cytoskeleton, and various types of enzymatic activities. These results suggest that IMP-1 expression is likely to play important roles in lung cancer development and progression, and that IMP-1 is a prognostic marker and a promising therapeutic target for treatment of lung cancer.03-24-2011
20100189724METHOD FOR SCREENING OF PATIENT TO BE ADMINISTERED WITH PHARMACEUTICAL AGENT COMPRISING ANTI-CANCER ANTIBODY AS ACTIVE INGREDIENT - The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.07-29-2010
20090208514METHOD OF DIAGNOSING ESOPHAGEAL CANCER - In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a 08-20-2009
20120039915GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.02-16-2012
20100172921INHIBITION OF TUMOR METASTASIS BY ANTI NEUROPILIN 2 ANTIBODIES - The application provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.07-08-2010
20110064749COMPOSITIONS COMPRISING IMMUNOREACTIVE REAGENTS AND SAPONINS, AND METHODS OF USE THEREOF - The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.03-17-2011
20110064747METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided.03-17-2011
20120301489Jagged-Binding Agents and Uses Thereof - Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.11-29-2012
20120301488ANTI-CD40 ANTIBODIES AND METHODS OF USE - The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.11-29-2012
20110076286METHODS OF INHIBITING UNWANTED CELL PROLIFERATION USING HEDGEHOG ANTAGONISTS - The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.03-31-2011
20100266618COMPOSITIONS AND METHODS FOR AUGMENTING ACTIVITY OF ONCOLYTIC VIRUSES - Disclosed are compositions and methods for augmenting activity of oncolytic viruses. Virus activity is augmented by sensitizing cancer or tumour cells through modulation of the Endoplasmic Reticulum (ER) stress response pathway, for instance by introducing into a tumour cell an agent effective to modulate ER stress response and sensitize the tumour cell. The tumour cells are then contacted with an oncolytic virus in an amount effective to reduce viability of the sensitized tumour cell. The oncolytic virus is thereby rendered more effective at lysing or killing the sensitized tumour or cancer cells.10-21-2010
20120009204Treatment of Metastatic Breast Cancer - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.01-12-2012
20100285039B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells - Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer cells that increases the resistance of the cancer cells to CTL mediated cytolysis and to Fas induced cell death. It is believed that blocking the transmission of the anti-apoptotic signal by B7-H1 increases the susceptibility of the cancer cells to apoptosis and CTL cytolysis thereby enhancing the death of cancer cells. Preferred compounds or B7-H1 antagonists include antibodies that bind to B7-H1, B7-H1 receptors, or ligands of B7-H1 such as PD-I or B7-1. Additional B7-H1 antagonists include small molecules, for example small molecules that bind the cytoplasmic portion of B7-H1 or the extracellular portion of B7-H1 and inhibit, reduce, block or interfere with B7-H1 signal transduction. Methods for treating one or more symptoms associated with cancer or hyperproliferation are also provided.11-11-2010
20120114671THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION - The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.05-10-2012
20120114670METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS - Disclosed are compositions and methods related to new targets for cancer treatment.05-10-2012
20100104587METHODS OF MODULATING THE NEGATIVE CHEMOTAXIS OF IMMUNE CELLS - The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.04-29-2010
20120114672Antibodies Specific to Cadherin-17 - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed.05-10-2012
20120058130COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS - Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).03-08-2012
20120156226Marker Differentially Expressed in Cancer Stem Cells and Methods of Using Same - The present invention pertains to methods and agents that target nanog expression or activity for treating or preventing cancer. Alternative methods involve diagnosing cancer stage or type by identifying presence of cancer cells expressing nanog. Other embodiments relate to methods of identifying agents that modulate nanog.06-21-2012
20120207772ANTI-MUC1 ALPHA/BETA ANTIBODIES - The present invention provides antibodies that simultaneously bind the α- and β-subunits of an intact MUC1 protein, and methods for making and using such antibodies.08-16-2012
20110091487MELANOMA BIOMARKER AND METHODS OF USES - The present invention relates to the use of TROY, also called tumor necrosis factor receptor superfamily, member 19 (TNFRSF19) also called toxicity and JNK inducer (TAJ), in diagnosis and therapy of non-epithelial cancers, such as melanoma. Accordingly, the invention provides in vitro and in vivo diagnostic and/or prognostic methods for cancers, other than epithelial cancers, preferably melanoma, comprising analyzing TROY expression in a biological sample from an individual or in an individual, wherein expression of TROY in non-epithelial cells, such as in melanocytes, in indicative the biological sample or the individual containing malignant cells, such as malignant melanoma cells. The invention also provides therapeutic use of TROY targeting molecules, such as TROY antibodies or TROY targeting RNA interfering agents for treatment of cancer wherein the cancer cells express TROY.04-21-2011
20110091486INHIBITION OF POST-RADIATION TUMOR GROWTH - Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.04-21-2011
20090142358HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF - The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.06-04-2009
20100291112Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives - The present invention relates to a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises (a) a first immunoglobulin domain comprising a V11-18-2010
20110104183USE OF SIP1 AS DETERMINANT OF BREAST CANCER STEMNESS - The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIP1 nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors.05-05-2011
20100092492VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases and disorders characterized by undesirable or excessive endothelial cell proliferation or neovascularization. The monoclonal antibodies and receptors of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF in a test sample.04-15-2010
20100092490METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR - The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.04-15-2010
20120121612FERMENTED WHEAT GERM PROTEINS (FWGP) FOR THE TREATMENT OF CANCER - The present invention provides compositions comprising the component of fermented wheat germ extract (“FWGE”) active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors, and methods of making and using such compositions. The active component from FWGE comprises polypeptides having a molecular weight in the range of about 5-100 kiloDaltons (kD), for example, a molecular weight in the range of about 12-50 kD. Exemplary polypeptides from FWGE determined to be active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors are listed in Table 1.05-17-2012
20120164160MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.06-28-2012
20100209438OVR110 Antibody Compositions and Methods of Use - The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.08-19-2010
20120213803METHODS FOR DIAGNOSING AND TREATING ENCEPHALITIS OR EPILEPSY - This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an anti-body to a GABA08-23-2012
20120219568EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER - Compositions containing epidithiodioxopiprazines and methods of their use are provided. Epidithiodioxopiprazines can be isolated from natural resources or synthesized de novo. Moreover, epidithiodioxopiprazines, including Verticillin A, are shown to effectively sensitize multiple types of tumor cells to TRAIL-induced apoptosis. In addition, epidithiodioxopiprazines, including Verticillin A, are shown to effectively overcome cancer cell resistance to existing drugs (i.e. Etoposide, Cisplatin, 5-FU and Doxorubicin). Therefore, compositions and methods are provided for use in sensitizing target cancer cells to death receptor- and other anticancer drugs-induced apoptosis. Methods of treating cancer in a subject in need thereof are also provided.08-30-2012
20120219570G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.08-30-2012
20120219569USE OF AN ANTI-CD151 ANTIBODY IN THE TREATMENT OF CANCER - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.08-30-2012
20120135011Method for in vivo expansion of T regulatory cells - Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells.05-31-2012
20120171226ANTIBODIES TO HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN - The present disclosure relates to anti-high molecular weight melanoma associated antigen (HMW-MAA) antibodies which bind to human HMW-MAA. Such antibodies may be used to treat diseases or disorders characterized by expression of HMW-MAA including cancer, for example, melanoma, basal cell carcinoma, ALL or AML.07-05-2012
20100047257ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.02-25-2010
20120177666ANTI-TGF-BETA RECEPTOR II ANTIBODIES - The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGFβRII), pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and fibrosis.07-12-2012
20120315287MIC-BINDING ANTIBODIES AND METHODS OF USE THEREOF - The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.12-13-2012
20100297153Binding molecules for treatment and detection of cancer - Provided are new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The tumor-associated antigens are expressed on cancer cells and binding molecules capable of specifically binding to the antigens can be used in the diagnosis, prevention and/or treatment of cancer.11-25-2010
20090017046Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof - Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.01-15-2009
20110045005COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.02-24-2011
20110217319METHODS OF USE OF SIALOADHESIN FACTOR-2 ANTIBODIES - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents09-08-2011
20090324617Cancer specific glycans and use thereof - The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.12-31-2009
20100233187GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCEROUS CELLS - The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.09-16-2010
20110262465PROSTATE STEM CELLS AND USES THEREOF - Prostate stem cells and prostate cancer stem cells and their use in treating prostate cancer and regenerating prostate tissue are disclosed.10-27-2011
20120282278ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF - The invention relates to an antigen binding site for binding to a P2X11-08-2012
20100150948MATERIALS AND METHODS FOR IMPROVED IMMUNOGLYCOPROTEINS - Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immuno-glycoproteins.06-17-2010
20120100158ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME - A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.04-26-2012
20120100157Biomarker and Method for Predicting Sensitivity to MET Inhibitors - Methods for determining the responsiveness of a Met-related cancer in a subject to treatment with a Met inhibitor. Kits for performing the disclosed methods are also provided. The present invention also provides a method of treating glioblastomamultiforme (GBM) in a subject in need thereof, the method comprises administering a therapeutically effective dose of a Met inhibitor in combination with a therapeutically effective dose of a epithelial growth factor receptor (EGFR) inhibitor.04-26-2012
20110159017TRYTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS - The unexpected expression of tryptophan 2,3-dioxygenase (TDO2) in cancer cells and tumors has been established. Methods for diagnosing cancer based on the expression of TDO2 are provided, as are methods for treating cancer and inhibiting the growth of cancer cells by inhibiting TDO2, as well as pharmaceutical compositions.06-30-2011
20130022624ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×1001-24-2013
20130171174ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY AND USES THEREOF - An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.07-04-2013
20130177579ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS USING SAME - The present disclosure relates to antibodies that recognize a carbohydrate on transferrin receptor expressed by nonhematopoietic tumor or cancer cells and uses thereof.07-11-2013
20130177578Treatment of Metastatic Breast Cancer - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.07-11-2013
20130171173METHOD FOR PRONGF ASSAY FOR IN VITRO DIAGNOSIS OF CANCER IN PARTICULAR BREAST, THYROID OR LUNG CANCER AND THERAPEUTIC USE OF PRONGF - A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.07-04-2013
20130115229METHOD FOR DETECTING MALIGNANT TUMOR CELLS - Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.05-09-2013
20100278844Cancer Marker and Therapeutic Target - Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.11-04-2010
20080199482Method For Inhibiting The Transendothelial Migration Of Cells Such As Leukocytes Or Tumor Cells By A Cd-Binding Substance And Uses Thereof - The invention provides a method for inhibiting the transmigration of cells, such as leukocytes or tumor cells, across endothelial cells, by contacting said cells with a CD81 binding agent. Furthermore, the invention provides a method for retarding or inhibiting tissue damage in a subject suffering from an inflammatory disorder, or tumor metastasis, comprising administering to said subject a pharmaceutical composition containing a CD81 binding agent capable of inhibiting transmigration of cells, such as leukocytes and tumor cells.08-21-2008
20110223182MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.09-15-2011
20110256155METHODS TO MOLECULARLY CHARACTERIZE CIRCULATING TUMOR CELLS - The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles.10-20-2011
20110256154ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.10-20-2011
20130149320Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer - The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer.06-13-2013
20130149319ANTICANCER COMPOSITION - Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).06-13-2013
20120276122METHODS FOR DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS - Methods for the diagnosis or prognosis of cellular proliferative disorders by detecting expression of PKC in cancer cells or tumor cells are provided herein. Also provided are methods for treating a melanocyte proliferative disorder with agents that modulate the translocational activity of ATF2 and/or PKCε activity.11-01-2012
20100303834COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.12-02-2010
20100310583LET-7 MICRORNA AND MIMETICS THEREOF AS THERAPEUTICS FOR CANCER - The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. In some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells.12-09-2010
20100316655COMPOUNDS WITH MDR1-INVERSE ACTIVITY - Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the structure:12-16-2010
20130156795METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF - The invention provides for methods for treating nervous system cancers in a subject. The invention further provides methods for treating nervous system tumor cell invasion, migration, proliferation, and angiogenesis associated with nervous system tumors.06-20-2013
20110311557RECIPROCAL SERUM/PLASMA EXCHANGE FOR THE TREATMENT OF CANCER - Techniques for treating cancer are provided. The techniques include obtaining an amount of serum and/or plasma from at least a first patient with a given type of cancer and administering at least a portion of the serum and/or plasma obtained from the first patient to at least a second patient with the same or different type of cancer. Administering the serum and/or plasma obtained from the first patient to the second patient includes administering a therapeutically effective amount of one or more immunoglobulins and one or more soluble receptors corresponding to each immunoglobulin so as to enable reconstitution of a humoral immune system of the second patient to thereby treat the cancer in the second patient.12-22-2011
20130189285ANTIBODIES AGAINST RAMP3 - Isolated antibodies capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor wherein the antibodies are of IgG, IgA or IgM isotype are provided, together with nucleic acid molecules encoding such antibodies, vectors comprising such nucleic acid molecules, host cells comprising such vectors, and methods of making the disclosed antibodies using such host cells. Also provided are compositions including the disclosed antibodies and methods of treating disorders, such as tumors, inflammatory disorders, cardiovascular disorders and osteoporosis, by administering such compositions.07-25-2013
20110318369ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER AFFINITY, AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VIRAL INFECTION AND AUTOIMMUNE DISEASE - An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody.12-29-2011
20120020989METHODS OF TREATING COLORECTAL CANCER - The present invention provides a pharmaceutical composition and a treating method for colorectal cancer which is difficult for a surgical treatment, comprising an anti-A33 human antibody and a chemotherapy agent in combination. Based on the present invention, a pharmaceutical composition and a treating method comprising the combination of anti-A33 human antibody with CPT-11 (irinotecan) can exhibit a certain degree of antitumor effect on a patient with colorectal cancer who is found recurrence after previously-initiated therapy and/or a patient with colorectal cancer who is difficult to be cured by existing treatments for colorectal cancer.01-26-2012
20120027779Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers - The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.02-02-2012
20130195896COMPOSITIONS AND METHODS FOR THE TREATMENT OF A NEOPLASIA - The invention provides methods for the treatments of neoplasia featuring agents that interfere with the expression or activity of a TNFa receptor.08-01-2013
20120294873ANTI-EpCAM IMMUNOGLOBULINS - The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks.11-22-2012
20130095122Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein - The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies. Considering the amino acid sequence of this protein deprived from the signalling peptide, the residues involved in the interaction are selected from: A7, K53, G54, R55, R57, L58, F59, V64, Y69, R85, D87, K91, and more preferably C17, S18, Y47, G61, G66, D67, L76, W102, D103, C106.04-18-2013
20120093838GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO A HER2 ANTIBODY CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization.04-19-2012
20120093837COMPOSITIONS AND METHODS FOR DETECTING EGFR IN CANCER - The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.04-19-2012

Patent applications in class Cancer cell